Combining BCMA-targeting CAR T cells with TCR-engineered T-cell therapy to prevent immune escape of multiple myeloma

Blood Adv. 2023 Oct 24;7(20):6178-6183. doi: 10.1182/bloodadvances.2023010410.

Authors

Tassilo L A Wachsmann¹, Miranda H Meeuwsen¹, Dennis F G Remst¹, Karen Buchner¹, Anne K Wouters¹, Renate S Hagedoorn¹, J H Frederik Falkenburg¹, Mirjam H M Heemskerk¹

Affiliation

¹ Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands.

No abstract available

MeSH terms

B-Cell Maturation Antigen
Cell- and Tissue-Based Therapy
Humans
Multiple Myeloma* / therapy
Receptors, Chimeric Antigen* / genetics
T-Lymphocytes

Substances

B-Cell Maturation Antigen
Receptors, Chimeric Antigen